暂无摘要。

暂无摘要。

Lichen sclerosus (LS) is an uncommon, chronic, inflammatory mucocutaneous disorder found predominantly in females with unknown etiology. It presents as a white sclerotic plaque commonly located on the anogenital area. Extragenital LS is less prevalent, and LS affecting the oral mucosa is extremely rare, with only 39 biopsy-confirmed cases reported in the literature. Due to its several mimicking conditions, histological examination is usually required for a definitive diagnosis, particularly in patients with oral LS. Current evidence-based treatment recommendations for oral LS are unavailable; however, most cases tend to improve after treatment with topical or intralesional corticosteroids. We report a case of a 58-year-old female referred from the otolaryngology department for evaluating an asymptomatic whitish sclerotic plaque on the lower lip mucosa that had existed for 1 year. Following a punch biopsy, the patient was diagnosed with LS of labial mucosa. The condition improved after 2 months of treatment with topical and intralesional corticosteroids. The present case report raises awareness in recognizing oral LS and contributes to knowledge of this rare disorder.

There are dermatoses that arise within healed zosteriform sites, such as granulomas annulare, acneiform eruptions, psoriasis, lichen planus, and giant cell lichenoid dermatitis \"GCLD.\" Nonetheless, graft-versus-host disease should be considered and ruled out, especially in patients post-bone marrow transplant. Herein, we report a case of GCLD manifesting within healed zosteriform sites.

Immune checkpoint inhibitors such as anti-PD-1 receptor antibodies have been shown to be effective in patients with advanced gastric cancer. However, there is a growing concern about immune-related adverse events. A case of a patient with gastric adenocarcinoma who developed toxic epidermal necrolysis (TEN) induced by sintilimab and subsequently developed lichenoid dermatitis is reported. TEN was diagnosed according to a history of sintilimab use, clinical symptoms and physical examination. During hospitalization, the patient developed recurrent fever caused by bacteremia and recovered from TEN after anti-infection and anti-inflammatory treatments. However, when TEN was controlled, the patient developed the lesional manifestations of lichenoid dermatitis. To date, no cases of lichenoid dermatitis after TEN have been reported following the use of PD-1 inhibitors.
PD-1 inhibitors are drugs that help fight stomach cancer but can sometimes cause skin problems. Most skin problems are minor and do not have a serious impact on the patient\'s health. However, life-threatening skin problems such as toxic epidermal necrolysis (TEN) can sometimes happen. This case report describes a patient with stomach cancer who had lichenoid dermatitis (another skin problem) after TEN, following the treatment of his cancer with PD-1 inhibitors. To the best of our knowledge, it is very rare to experience both skin problems after treating cancer with PD-1 inhibitors. This rare phenomenon is reported to bring more attention to it. More research is needed to determine how to treat this problem better.

暂无摘要。

Lichenoid dermatitis can be a perplexing entity encompassing an array of cutaneous disorders. Two hundred forty-three (243) cases of otherwise unclassifiable lichenoid dermatitis were examined histologically employing a special cytokeratin stain. Occult squamous cell carcinoma was detected in three of the 243 cases, uncovered by special immunohistochemistry staining within histologic specimens of lichenoid dermatitis. We recommend staining for cutaneous cancer becoming a routine practice in evaluating cutaneous lichenoid dermatitis.

BACKGROUND: Imatinib Mesylate (IM), a tyrosine kinase inhibitor, has been reported to cause several adverse reactions, most of them with cutaneous involvement. Non- Lichenoid IM associated skin reactions have been sufficiently- recorded. To our knowledge, Lichenoid Drug Eruption (LDE) is recorded in a minority of registries.
METHODS: To describe an LDE induced case by IM treatment.
RESULTS: Histological Confirmation and promptly dermatological consultation relieved successfully the cutaneous adverse event.
CONCLUSIONS: Ongoing expansion of IM usage in a wide spectrum of new indications is more likely to make physicians experience such LDE cutaneous side effects more often. Hence, they should be highly suspicious to early detect these distinct histologic entities, handle these undesired complications and guarantee satisfactory immediate outcomes, avoiding frivolous IM dosage modifications.

Abstract- A syndrome of uveitis, associated with depigmentation and erosion of areas of skin and mucous membrane on the head and, in one dog, on the scrotum, was observed by the authors in two male Siberian Huskies. These clinical signs are similar to the Vogt-Koyanagi-Harada syndrome in man. Histological examination of the affected skin revealed a lichenoid dermatitis of the upper dermis. Intensive topical therapy with mydriatic and cycloplegic drugs and corticosteroids coupled with systemic prednisolone and azathioprine were used to control the disease. Both subjects were monitored for 10 months and retained useful vision. The skin and oral lesions resolved. Résumé- Un syndrome d\'uvéite idiopathique, non traumatique, associée à une dépigmentation et une érosion de zones cutanée et muqueuse sur la tête et, chez un chien, sur le scrotum, a été observé par les auteurs sur deux mâles Siberian Huskies. Ces signes cliniques évoquent le syndrome de Vogt-Koyanagi-Harada de l\'homme. Un examen histologique de la peau atteinte a montré l\'existence d\'une dermatite lichénoide du derme superficiel. Un traitement topique intensif par des médicaments mydriatiques et cyclopégiques, ausociéà l\'administration systémique de prednisolone et d\'azathioprine a été utilisé pour controler la maladie. Les 2 sujets ont été observés pendant 10 mois et ont retrouvé une vision utile. Les lésions cutanées et orales ont guéri. Zusammenfassung- Bei zwei Husky-Rüden wurden von dem Autoren ein Krankheitssyndrom aus idiopathischer, nicht-traumatisch bedingter Uveitis, Depigmentierung einzelner Haut- und Schleimhautbezirke am Kopf und-bei einem Hund-am Skrotum festgestellt. Diese Symptome ähneln dem Vogt-Koyanagi-Harada-Syndrom beim Menschen. Bei der histologischen Untersuchung von Biopsien der erkrankten Hautbezirke wurde eine lichénoide Dermatitis der oberen Dermisschichten diagnostiziert. Durch eine intensive örtliche Behandlung mit Mydriatica, Cycloplegica und Corticosteroiden in Kombination mit systemischer Prednisolon- und Azathioptringabe konnte die Erkrankung unter Kontrolle gehalten werden. Beide Patienten wurden 10 Monate überwacht und sahen zufriedenstellend aus. Die Veränderungen an Haut und Mundhöhle bildeten sich zurück. Resumen  Los autores describen un síndrome de uveitis no traúmatica idiopática asociada a una despigmentación y erosión de áreas de la piel y de las membranas cutáneas de la cabeza, en un perro y del escroto en otro perro. Ambos animales pertenecían a la raza Siberian Husky. Estos signos clínicos se asemejan en los descritos en la síndrome de Vogt-Koyanagi-Harada de las personas. El examen histológico mostró la presencia de un infiltrado inflamatorio liquenoide en la dermis superficial. Para el tratamiento a la enfermedad se aplicaron corticosteroides y fármacos midriáticos y ciclopéjicos de forma tópica y prednisona de forma sistémica. Ambos animales fueron controlados durante diez meses y mantuvieron la visión. Las lesiones orales y cutáneas se resolvieron por completo.

Pembrolizumab is an immune checkpoint inhibitor approved for use in many cancer types such as non-small cell lung cancer (NSCLC), metastatic melanoma, head and neck cancers, hepatocellular carcinoma, and renal cell carcinoma. There are many reported cases of patients on immunotherapy who have discontinued treatment due to the development of immune-related adverse effects (irAE). Recognition of the histopathologic patterns of dermatologic toxicities due to immunotherapy will become increasingly important for ensuring appropriate management and optimal patient care. Here, we present a case of a 72-year-old man with metastatic carcinoma of unknown primary origin treated with pembrolizumab who developed an immune-related cutaneous adverse event (ircAE) in the form of lichenoid dermatitis.